Verastem, Inc. (VSTM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on August 13, 2025. The filing discloses updated safety and efficacy data from the Phase 1/2 clinical study of VS-7375 (GFH375 in China), a KRAS G12D inhibitor, conducted in China by partner GenFleet Therapeutics. The data is scheduled for presentation at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer in September 2025.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial progress and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details significant clinical developments for the VS-7375 program as of the July 15, 2025 data cutoff:
- Study Population: 142 patients total, including 28 with advanced non-small cell lung cancer (NSCLC), 85 with pancreatic ductal adenocarcinoma (PDAC), and 29 with other solid tumors.
- NSCLC Efficacy (Recommended Phase 2 Dose of 600 mg):
- Overall Response Rate (ORR): 68.8% (11/16 patients).
- Disease Control Rate (DCR): 93.8% (15/16 patients).
- NSCLC Efficacy (All Dose Levels): Among 26 evaluable patients, ORR was 57.7% and DCR was 88.5%.
- Safety Profile:
- Most common treatment-related adverse events (TRAEs) included diarrhea, vomiting, nausea, and anemia, predominantly Grade 1 or 2.
- TRAEs occurred in 27.5% of patients; severe adverse events (Grade 3+) occurred in 7.7%.
- No TRAE-related deaths were reported.
Outlook, Management Commentary, and Risks
Management highlights VS-7375 as the lead program from the collaboration with GenFleet. The U.S. Investigational New Drug (IND) application was cleared in April 2025, with a Phase 1/2a trial initiated in June 2025. The filing notes that the data will be presented in a mini oral format at an upcoming international conference. No specific financial guidance or new risk factors were disclosed in this report beyond standard clinical trial uncertainties.
Key Facts for Investor Verification
- Verify the confirmation status of the 68.8% ORR in NSCLC patients at the 600 mg dose, as the filing notes these figures include both confirmed and unconfirmed responses.
- Monitor the initiation and early data readouts from the U.S. Phase 1/2a trial initiated in June 2025 to assess consistency with the Chinese data.
- Review the full safety data for long-term follow-up, noting the median follow-up time was 4.5 months as of July 2025.
- Confirm the timeline for the oral presentation at the IASLC 2025 conference in Barcelona (September 6-9, 2025).